Personalizing Steroid Duration in Asthma
Researchers tested whether a readily available biomarker can individualize systemic corticosteroid prescribing during asthma-related hospitalizations.
-
By
-
Kathryn Wighton
-
February 3, 2026
-
Clinical Scorecard: Personalizing Steroid Duration in Asthma
At a Glance
| Category | Detail |
|---|
| Condition | Asthma exacerbation |
| Key Mechanisms | Eosinophil-guided corticosteroid duration |
| Target Population | Adults hospitalized for asthma exacerbation |
| Care Setting | Tertiary hospitals |
Key Highlights
- Eosinophil-guided approach reduces cumulative steroid exposure.
- Treatment failure rates were similar between eosinophil-guided and usual care.
- No deaths or severe adverse events reported.
- 60% of participants had eosinophilic exacerbations.
- Further research needed for generalizability.
Guideline-Based Recommendations
Diagnosis
- Assess baseline blood eosinophil counts in hospitalized asthma patients.
Management
- Use eosinophil counts to guide systemic corticosteroid duration.
Monitoring & Follow-up
- Monitor for treatment failure and adverse events.
Risks
- Potential bias due to open-label design.
Patient & Prescribing Data
Adults aged 21 years or older with asthma exacerbation.
Prednisolone dosing based on eosinophil count: 3 days for <300 cells/µL, 5 days for ≥300 cells/µL.
Clinical Best Practices
- Consider eosinophil counts in treatment planning for asthma exacerbations.
- Evaluate the need for systemic corticosteroids based on eosinophilic status.
References
